成人急性感染性腹泻临床对策研究

The Clinical Therapeutic Study on the Adult Acute Infected Diarrhoea

目的 :探讨成人急性感染性腹泻的临床对策 ,观察庆大霉素与思密达联合口服的疗效。方法 :对 135例急性感染性腹泻患者随机分为思密达联合庆大霉素治疗组 71例和复方苯乙哌啶片、氟哌酸胶囊 ,黄连素片对照组6 4例进行三日疗法观察 ,观察两组病人的疗效、副作用、临床症状的改善率等。结果 :两组患者临床症状均有改善 ,治疗组治愈率达 97.18% ,且无不良反应发生 ,对照组治愈率为 85 .94% ,有 12 .5 %出现了不良反应 ,有显著性差异(P <0 .0 5 ) ,两组对临床症状的改善有非常显著性差异P <0 .0 1) ,治疗组明显优于对照组。结论 :思密达冲剂联合庆大霉素片口服治疗成人急性感染性腹泻疗效好于对照组 ,且非常符合WHO对抗腹泻药规定的六条标准。

Objective To investigate the clinical therape ufic effect of Gentamycinum united Smecta to the adult acute infected Diarrhoea. Methods We divided the 135 cases into two groups with random, one group treated with Gentamycinum united Smecta(71 cases) and another with Diphenoxylate, Norfloxacin and Berberine Hydrochleride (64 cases) according to a three day therapeutic observation; the therapeutic effects, by-effects and the improvement of clinical characters. Results The clinical characters of both groups were improved. The cure rate of the first group is 97.18%, with no by-effect that of the second group with 85.94% cure rate 12.5% by-effect (P<0.05). The first group has an obvious advantage over the second group on the clinical characters (P<.001). Conclusions Smecta united Gentamycinum has a good therapeutic effect on the adult acute infected Diarrhoea while the control group (Diphenosylate etal.) less. This is in keeping with the WHO 6 criteria of the anti-diarrhoea drugs.